Teva bids $40bn for Mylan
Pharmaceutical company Teva has offered to buy fellow drug maker Mylan in a deal that could be worth $40 billion.
In the proposal, confirmed yesterday (April 21), Teva offered Mylan $82 per share.
Last week, Mylan’s executive chairman Robert Coury dismissed rumours of a merger with Israel-based Teva.
He said at the time: “Such a combination is without sound industrial logic or cultural fit”.
Earlier this month, Mylan made a bid of nearly $30 billion to buy Irish consumer pharma company Perrigo. That offer was rejected yesterday.
Teva described its offer as a “more attractive alternative for Mylan stockholders than Mylan’s proposed acquisition of Perrigo”.
It said that a combination of the companies could “transform the global generics space”, and could have annual revenues of $30 billion.
The combined company would be able to focus on “more complex, hard-to-produce durable products”, Teva added.
Teva said that if it were to join forces with Mylan the two companies would have a combined pipeline of more than 400 pending Abbreviated New Drug Applications in the US.
Erez Vigodman, Teva’s president and chief executive, said: “Our companies share years of experience and success leading the generic industry and building strong presences in specialty and biologics.
“Mylan’s business is a natural fit with our own and is highly complementary to it.”
Mylan did not respond to a request for comment.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk